Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence GEGDFLAEGGGVR
Primary information
sequence IDSeq_2601
Peptide sequenceGEGDFLAEGGGVR
CancerPDF_ID CancerPDF_ID6, CancerPDF_ID165, CancerPDF_ID192, CancerPDF_ID225, CancerPDF_ID642, CancerPDF_ID1024, CancerPDF_ID1231, CancerPDF_ID2295, CancerPDF_ID3255, CancerPDF_ID8504, CancerPDF_ID9665, CancerPDF_ID11465, CancerPDF_ID12685,
PMID16896061,19728888,19728888,19728888,19795908,16395409,21136997,21136997,21267442,23667664,21533267,26992070,25168216
Protein NameFibrinogen alpha chain,Fibrinopeptide A,phospho-fibrinopeptide A,Phospho-fibrinopetide A,Fibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain
UniprotKB Entry NameFIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN
FluidSerum,Serum,Serum,Serum,Plasma,Serum,Serum,Plasma,Serum,Serum,Serum,Serum,Serum
M/Z1263.6,1263.5958,1616.6366,1616.6366,632.3,1263.6,1262.58913,1262.589,1264,1262.59,632.28,1262.5891,NA
Charge1,NA,NA,NA,2,1,1,1,NA,1,2,NA,NA
Mass (in Da)1263.59,NA,NA,NA,NA,NA,NA,NA,NA,1264.34,NA,1263.600756,NA
fdrNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1262.59
Profiling TechniqueMALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS,LC-MS,LC-MS
Peptide Identification techniqueQ/TOF MS/MS,LC-MS/MS,LC-MS/MS,LC-MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS,LC-MS/MS
Quantification TechniqueNA,NA,NA,NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free,Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free
FDRNA,NA,NA,NA,less than 7%,less than 1 “5,0.001,NA,NA,NA,1.49,FDR 1 %,NA
CancerPDF_ID CancerPDF_ID6, CancerPDF_ID165, CancerPDF_ID192, CancerPDF_ID225, CancerPDF_ID642, CancerPDF_ID1024, CancerPDF_ID1231, CancerPDF_ID2295, CancerPDF_ID3255, CancerPDF_ID8504, CancerPDF_ID9665, CancerPDF_ID11465, CancerPDF_ID12685,
p-Value1.00E-05,less than 0.01,less than 0.05,less than 0.01,NA,2.74E-16,1.34E-04,NA,NA,NA,1.98E-21,NA,6.16E_04
SoftwareMASCOT,MASCOT(v 2.0.04 for Windows),MASCOT(v 2.0.04 for Windows),MASCOT(v 2.0.04 for Windows),FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),NA,MASCOT,MASCOT,SEQUEST and Maxquant,MASCOT
Length13,13,16,16,13,13,13,13,13,13,13,13,13
Cancer TypeMetastatic thyroid carcinomas,"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy",Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,Stomach adenocarcinoma,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Melanoma,Renal cell carcinaoma
DatabaseNCBI refseq Protein Database,SwissProt Database (release 54.7),SwissProt Database (release 54.7),SwissProt Database (release 54.7),NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,NA,Swissprot Database (57.4),SwissProt Database,SwissProt Database
ModificationNA,NA,Ser at 3rd is phosphorylated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","27 patients, 13 normal individuals","42 normal, 28patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,41 and 21 patients are in training dataset and testing dataset respectively; 21 and 12 Normal healthy individual s are in training dataset and testing dataset respectively,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples,"30 RCC patients and 30 healthy controls for training dataset and 6 RCC patients, 6 control in independent validation dataset"
RegulationDifferentially expressed between cancer vs normal samples,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS and Peptide signature for differentiation between healthy and NSCLC patients,Differentially expressed between NSCLC patients vs healthy volunteers,NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.2, 0.24 and 0.23 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal,NA,NA,NA,Differentially expressed between Lung cancer vs control,"Present in 5 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples.",Upregulated in cancer v/s Normal
ValidationIndependent validation,Independent validation,Independent validation,Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,Independent validation,NA,MRM-based validation of 19 candidates,na,Independent validation
Sensitivity95% on independent dataset,1,1,1,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,0.898,NA,NA,NA,NA,NA,100 % (for 19 peptide signatures)
Specificity95% on independent dataset,0.73,0.73,0.96,NA,NA,0.946,NA,NA,NA,NA,NA,NA
AccuracyNA,0.86,0.86,0.98,NA,97.5 % on validation dataset,0.917,NA,NA,NA,0.777,NA,AUC : 0.734
Peptide AtlasPeptideAtlas
IEDB462581